Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.10/Share

Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.10), versus ($0.21) reported last year. Revenue for the quarter came in at $424 thousand, versus $247 thousand reported last year.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture downgraded by TD Cowen on AI concerns
• Dutch Bros Inc. (BROS) PT Raised to $90 at DA Davidson on Sales/Earnings Upside